COVID-19 Vaccine Collaboration – Retrogenix & NINDS

The National Institute of Neurological Disorders and Stroke (“NINDS”) and Charles River High Peak (“Retrogenix”) will collaborate to screen pools of selected patient samples after the administration of SARS-Cov-2 vaccine and matching unvaccinated controls.

This collaboration will use Retrogenix’s unique Cell Microarray platform in a bid to identify the human cell surface/secreted protein binding profiles for the patient samples. The test and control patient samples will each be screened against Retrogenix’s most up to date library of human plasma membrane proteins, tethered human secreted proteins and heterodimer plasma membrane protein complexes. The purpose is to identify autoantibodies to host antigens that may be activated by the administration of SARS-Cov-2 vaccine. Identification of these antibodies will potentially provide a biomarker that could be followed in these vaccinated patients.

For more information or to talk to us about a project, please contact us.